TITLE: External Audits of DF/HCC Clinical Research SOP #: AUD-102 (formerly QA-706) Page: 1 of 8 Effective Date: 1/14/2016
|
|
- Virgil Stewart Ward
- 5 years ago
- Views:
Transcription
1 SOP #: AUD-102 (formerly QA-706) Page: 1 of 8 Effective Date: 1/14/ POLICY STATEMENT: Prompt notification is required to inform key associated leadership and study personnel of pending inspections and audits. The Overall Principal Investigator (PI) and the responsible Clinical Trials Office will manage the notifications and logistics to ensure appropriate, complete and timely alert. In the event of an audit from the Food and Drug Administration (FDA) or European Medical Association (EMA), for trials in which a Partners institution was involved in the study, PIs must ensure that the Partners designated officials (see section 6) are notified in addition to the DF/HCC officials. 2. BACKGROUND: All audits/inspections strive to ensure the protection of human subjects and the quality and integrity of the data and information submitted to the Institutional Review Board (IRB), Sponsor, and regulatory authorities. DF/HCC has a vested interest in the quality of the research that is performed at the facility and in maintaining its collective reputation as an outstanding research community. Because of the center s structure and many sources of funding and support, it is critical for it to have an overall understanding of the workings and results of any external audits/inspections. This allows DF/HCC to develop systems to resolve problems when necessary. 3. RESPONSIBLE PERSONNEL: 3.1. Overall Principal Investigator (PI) 3.2. Site Principal Investigator 3.3. Study Coordinator 3.4. Clinical Trials Office Director 3.5. The Office of Data Quality (ODQ) Data and Safety Monitoring Manager 3.6. Institutional Official (IO) 4. DEFINITIONS: 4.1. Clinical Trial Office: The institutional entity that provides centralized administrative services that help move cancer clinical trials from initial proposal through study completion External Audit: An independent examination of research related activities and documents to determine whether the research related activities were conducted, recorded, and accurately reported according to the protocol, sponsor s procedures, and the applicable regulatory requirements. This may include but is not limited to examinations requested or directed by the Food and Drug Administration (FDA), European Medical Association (EMA), National Institutes of Health (NIH), a National Cancer Institute (NCI)/Cooperative Group, regulatory authorities, a research sponsor, or their representatives.
2 SOP #: AUD-102 (formerly QA-706) Page: 2 of 8 Effective Date 1/14/ Institutional Official (IO): A senior official who, on behalf of a research institution, has the authority and responsibility for the oversight and administration of the institution s human subject research program Lead Research Team: The research team at the same physical location as the DF/HCC Overall PI. 5. PROCEDURE: 5.1. This notification and follow-up process does not apply to routine sponsor monitoring visits Initial Notification: It is the responsibility of the Overall PI or responsible clinical trials office to communicate impending inspections to DF/HCC as outlined in Section 6 below The Overall PI or designated research team member will notify the responsible clinical trials office within 1 business day of notification of any external group s plans to inspect or audit a protocol at DF/HCC, providing the following details: date, time, location, and purpose of the audit, as well as the identity of the auditors and the principal DF/HCC study contact. The Overall PI or designated research team member should also confirm which DF/HCC sites are to be reviewed as part of the audit or inspection The Overall PI or designated research team member will notify the Sponsor as soon as possible if notified of an inspection by regulatory authorities, such as the Food and Drug Administration (FDA) The responsible clinical trials office will notify the Office of Human Research Studies (OHRS), the Office of Data Quality (ODQ)Site clinical trials offices, and the Research Pharmacies involved in the study within 1 business day of notification providing the following details: date, time, location, and purpose of the audit, as well as the identity of the auditors and the principal DF/HCC study contact.
3 SOP #: AUD-102 (formerly QA-706) Page: 3 of 8 Effective Date: 1/14/ In the event of a regulatory agency inspection, the responsible clinical trials office must also notify the DF/HCC Associate Director of Administration, and the appropriate IO and IRB at the site of the Overall PI For any regulatory audit, OHRS and ODQ are to be included in all communications and meetings unless otherwise notified by either office that their participation will be limited Preparing for the Inspection or Audit: The responsible clinical trials office will schedule a one-on-one meeting with the Overall PI and lead site research team, or affected Site Responsible Investigator and research team in the case of site-based Cooperative Group or sponsor audits, to review trial status, coordinate and plan roles for the inspection and audit, including: Coordinating with Site Responsible Investigators, research teams and applicable clinical trial offices Reserving appropriate space Requesting any required documents (i.e. medical records, off-site storage) Ensuring all regulatory, pharmacy and subject records are accurate, complete and available for review by the external inspector/auditor A mock audit or review will be scheduled as deemed appropriate by the ODQ. Trials audited in the past six months may not be scheduled for a full ODQ mock audit During the Inspection or Audit: The responsible clinical trials office must communicate with all involved DF/HCC parities during the audit, including providing summaries of key information, as needed, to ODQ, OHRS, appropriate IOs and Site clinical trials offices.
4 SOP #: AUD-102 (formerly QA-706) Page: 4 of 8 Effective Date: 1/14/ During the Exit Interview: The following individuals will participate in the exit interview: Overall PI (as applicable), Site Responsible Investigators (as applicable), an ODQ representative, an OHRS representative (if it is a regulatory audit) and a responsible clinical trials office representative The responsible clinical trials office representative will determine if others need to be present for the findings The responsible clinical trials office representative, in collaboration with the ODQrepresentative, will record discussion points during the exit interview and will provide summaries of key findings to the involved research team and the Audit Committee. Any significant findings, such as the issuing of a Form FDA 483, clinical hold, suspension or other actionable finding, from regulatory agencies or external sponsors will be communicated the next business day (Monday Friday) to the OHRS, ODQ, appropriate IOs and the DF/HCC Associate Director of Administration If a Form FDA 483 is generated, the Overall PI will request a copy Following-up after the Inspection or Audit: The Overall PI and designated research team member will draft the preliminary response within 10 business days of the exit interview and send it to the responsible clinical trials office for review Any results, corrective action plans or follow-up correspondence must be communicated to the responsible clinical trials office and through them to the ODQ for Audit Committee review and other applicable offices or entities (e.g., OHRS, pharmacy, etc.) The responsible clinical trials office and other applicable offices will review and approve the preliminary response before sending it to the reviewing sponsor/agency Responses to Form FDA 483 are due at the FDA no later than 15 business days after the exit interview.
5 SOP #: AUD-102 (formerly QA-706) Page: 5 of 8 Effective Date: 1/14/16 6. DF/HCC External Audit Contact List DF/HCC EXTERNAL AUDIT CONTACT LIST It is the responsibility of the Overall Principal Investigator to notify DF/HCC entities in advance of an external audit. This checklist is intended for use in determining who needs to be notified of an external audit. DF/HCC ODQ Nicholas Farley Director, ODQ nfarley@partners.org Nareg Grigorian Data&Safety Monitoring Manager ngrigorian@partners.org OHRS Michele Russell-Einhorn, JD Senior Director, OHRS mrussell-einhorn@partners.org DF/HCC Research Pharmacy Sylvia Bartel Director, Research Pharmacy sbartel@partners.org Dana-Farber Cancer Institute* *Includes Dana-Farber Cancer Institute, Dana-Farber/Brigham and Women s Cancer Care and Dana-Farber/Boston Children s Cancer and Blood Disorders Center DFCI Clinical Trials Office DFCI Main Pharmacy Pediatric Pharmacy Anne Daoust Director Clinical Trials Compliance, DFCI CTO adaoust@partner.org Caroline Harvey Supervisor, Research Pharmacy charvey@partners.org Caroline Harvey Supervisor, Research Pharmacy charvey@partners.org
6 SOP #: AUD-102 (formerly QA-706) Page: 6 of 8 Effective Date: 1/14/16 Beth Israel Deaconess Medical Center BIDMC Cancer Clinical Trials Office Jonathan Dinsmore, PhD Director, BIDMC CCTO jdinsmor@bidmc.harvard.edu BIDMC Pharmacy Michael Mosny Research Pharmacy mmosny@bidmc.harvard.edu Heena Patel Research Pharmacy hpatel@bidmc.harvard.edu Hina Jolin Research Pharmacy ljoshi@partners.org Massachusetts General Hospital MGH Cancer Center Protocol Office Robert Herman Director, MGH CCPO rherman1@partners.org Shannon Himber Associate Director, CCPO shimber@mgh.harvard.edu MGH Pharmacy Lalit Joshi Research Pharmacy ljoshi@partners.org In the Event of an Audit from the FDA: The Overall PI must notify Partners Contacts Listed Below: Elizabeth Hohmann, MD Chair, Partners IRB ehohmann@mgh.harvard.edu AND Rosalyn Gray Director of Human Research Review and Compliance Rgray1@partners.org
7 SOP #: AUD-102 (formerly QA-706) Page: 7 of 8 Effective Date1/14/ Hosting Audits with the FDA 7.1. In preparation for the FDA Audit: The Primary Investigator should prepare a list of all active and inactive studies where he/she is the Principal Investigator. The FDA will request to see this list when they arrive. It should include: protocol #s, protocol titles, product names, names of sponsors and study start and end dates 7.2. In preparation for the FDA Audit: The Primary Investigator should assure that the FDA inspector will have access to any electronic research records that will be needed. This may involve requesting access to the Patient electronic medical records system from the Partners IT department. This should be done in advance of the inspector s visit if possible When the FDA Inspector arrives at the site, the Primary Investigator should be available to meet and greet the auditor, and accept and sign the Form FDA 482 (Notice of Intent to Audit) 7.4. The PI should ask to view the inspector s credentials, but do not photocopy them 7.5. Provide the auditor or inspector with a comfortable place to work with ample space to organize materials. Keep the room free of non-protocol materials or subject information. Lock any cabinets and drawers in the room The FDA inspector should be escorted by a designated member of the study team at all times they are within the institution Gather key study personnel and introduce them to the FDA auditor 7.8. It is recommended that all study documents be stored in a separate room from where the inspector is conducting the audit. Only those documents that are requested by the inspectorshould be brought into the conference room/office Copying Documents: During the course of the audit, FDA inspectors may make copies of documents as necessary, but are not permitted to remove original documents from the institution grounds. If the inspector requests copies of study documents, make sure to clearly document what was copied, and keep a log of the date of the request, the name of the document and the name of the staff member providing the document During the Inspection: The Overall PI should adjust his or her schedule and be available to address questions or requests the auditor or inspector may have during the audit. The Overall PI or designee designate should plan on checking-in at least three times during each day, once in the morning, mid-day and towards late afternoon or at the timeframes agreed upon with the auditor or inspector. If the Overall PI tells the auditor or inspector that he or she will be available at a given time, be sure to keep the time. Do not make the auditor or inspector wait.
8 SOP #: AUD-102 (formerly QA-706) Page: 8 of 8 Effective Date: 1/14/ The Overall PI will designate a research team member as a liaison to facilitate the auditor or inspector. This designated liaison (or point person) will function as the auditor or inspector s escort. The designated liaison/escort will act as the coordinator for the audit and will keep written record of all audit related activities, including all document requests or requests for personnel interviews. Upon request, all research team members should be available to answer questions of which they have direct knowledge Confirm with the auditor or inspector his or her preference for handling issues and queries. Provide the appropriate pager number and paging instructions in case he or she needs to reach the Overall PI or the designee prior to the agreed meeting time. Remember to track all requests from the auditor or inspector and make photocopies, if appropriate During the audit, it is likely the auditor or inspector will make observations relating to the conduct of the trial, documentation, etc. The designated liaison/escort should work with the research team to make every effort to address and correct these observations while the audit or inspection is taking place Do not volunteer information; answer all questions briefly, honestly and accurately. Do not elaborate on a question unless questioned further for detail. When appropriate, limit responses to yes or no answers. Only answer questions of which you have direct knowledge. Be confident that your response is accurate and factual and be prepared to supply supporting documentation Limit offers of hospitality to simple beverages such as water, coffee, tea or juice. It is not appropriate to provide food items The Exit Interview: At the end of the inspection, the FDA inspector will conduct an exit interview. Refer to section 5.5 above for a list of required attendees. Interactions during the exit interview should take place primarily between the Overall PI and the inspector. If an FDA Form 483 is issued, make sure to obtain a copy before the inspector leaves. Refer to section 5.6 above for response guidance. 8. APPLICABLE REGULATIONS & GUIDELINES: 21 CFR 50 Protection of Human Research Subjects 21 CFR 54 Financial Disclosure by Clinical Investigators 21 CFR 56 Institutional Review Boards 21 CFR Investigational New Drugs Drugs for Human Use 21 CFR Investigational Device Exemptions 45 CFR 46 Protection of Human Subjects FDA Industry Guidelines and Information Sheets FDA Compliance Policy Guidance Programs: , , and RELATED REFERENCES: International Conference on Harmonisation E6 Version: 8 Effective Date: 1/14/2016 Last Reviewed Date: 12/08/2015
DANA-FARBER / HARVARD CANCER CENTER POLICIES FOR HUMAN SUBJECT RESEARCH TITLE:
POLICY #: EDU-100 Page: 1 of 5 1. POLICY STATEMENT: Individuals who participate in research activities overseen by DF/HCC must satisfy specific training requirements in order to conduct human subject research.
More information4.2. Clinical Trial Monitor (or Monitor): The person responsible for monitoring the data on behalf of the sponsor or contract research organization.
SOP #: MON-101 Page: 1 of 6 1. POLICY STATEMENT: The DF/HCC understands that external sponsors are required to monitor the progress of clinical investigations and ensure appropriate research data collection
More informationPrivacy Rule Overview
Privacy Rule Overview Protected Health Information (PHI) is private information that is subject to special treatment under the HIPAA Privacy Regulations. PHI can only be used or disclosed in research if
More informationStandard Operating Procedures
Clinical Monitoring and Site Verification Procedure Overview To define the standard procedures for preparation and documentation of site visits for clinical monitoring and spoke verification for any NETT
More informationDANA-FARBER / HARVARD CANCER CENTER STANDARD OPERATING PROCEDURES FOR HUMAN SUBJECT RESEARCH
SOP #: CON-100 Page: 1 of 9 Effective Date: 2/28/17 1. POLICY STATEMENT: The research team is responsible for obtaining and documenting the informed consent of each subject who participates in research.
More informationResearch Audits PGR. Effective: 12/04/2013 Reviewed: 12/04/2015. Name of Associated Policy: Palmetto Health Administrative Research Review
Effective: 12/04/2013 Reviewed: 12/04/2015 Name of Associated Policy: Palmetto Health Administrative Research Review Definitions Responsible Positions Equipment Needed Procedure Steps, Guidelines, Rules,
More informationTITLE: Reporting Adverse Events SOP #: RCO-204 Page: 1 of 5 Effective Date: 01/31/18
SOP #: RCO-204 Page: 1 of 5 1. POLICY STATEMENT: The research team is responsible for recognizing changes in subject health that may qualify as adverse events, classifying those results as defined in the
More informationEffective Date: April 2014 Revision: September 29, Executive Chair, Co-Chairs, NSHA REB Members, REB Office Personnel, Researchers.
TITLE: Standard Operating Procedure (SOP) External Inspections or Audits NUMBER: NSHA REB-SOP-9-002 Effective Date: April 2014 Revision: September 29, 2017 Applies To: Executive Chair, Co-Chairs, NSHA
More informationNN SS 401 NEURONEXT NETWORK STANDARD OPERATING PROCEDURE FOR SITE SELECTION AND QUALIFICATION
NN SS 401 NEURONEXT NETWORK STANDARD OPERATING PROCEDURE FOR SITE SELECTION AND QUALIFICATION SOP: NN SS 401 Version No.: 2.0 Effective Date: 21Oct2016 SITE SELECTION AND QUALIFICATION Supercedes Document:
More informationRequest to Use an External IRB as an IRB of Record
This form is to be used by investigators requesting use of an external IRB. Please submit this completed form, along with the required attachments, to the MHC IRB at hrpp@mclaren.org. (Please see SOP:
More information1. Department of Defense (DoD) Human Subjects Protection Regulatory Requirements
Information for Investigators: Headquarters, U.S. Special Operations Command Human Research Protection Office (HRPO) Human Research Protections Regulatory Requirements 1. Department of Defense (DoD) Human
More informationHIC Standard Operating Procedure. For-Cause Audits of Human Research Studies
HIC Standard Operating Procedure For-Cause Audits of Human Research Studies Background As part of the Wayne State University (WSU) Human Investigation Committee s (HIC) Human Research Protection Program,
More informationStudy Management PP STANDARD OPERATING PROCEDURE FOR Safeguarding Protected Health Information
PP-501.00 SOP For Safeguarding Protected Health Information Effective date of version: 01 April 2012 Study Management PP 501.00 STANDARD OPERATING PROCEDURE FOR Safeguarding Protected Health Information
More informationUnofficial copy not valid
Page 2 (9) CONTENTS 1. PURPOSE... 3 2. DEFINITIONS... 3 3. RESPONSIBILITY... 3 4. INVESTIGATOR SELECTION... 3 4.1 Identification of Investigator s... 3 4.2 Initial Contacts... 4 4.3 Distribution of Pre-Study
More informationEMA & FDA Inspections: Site perspective. Shandukani Research Centre
EMA & FDA Inspections: Site perspective Shandukani Research Centre Why were we inspected? Pharmaceutical company applied for registration of the study drug (Phase I/II dosing studies in paediatrics) Large
More informationAudits/Inspections Be Prepared for Anything
Audits/Inspections Be Prepared for Anything Practices, laboratories, institutions, and clinics that participate in clinical trials are subject to audits by a number of different entities. As a primary
More informationGeneral Administration GA STANDARD OPERATING PROCEDURE FOR Sponsor Responsibility and Delegation of Responsibility
General Administration GA 102.01 STANDARD OPERATING PROCEDURE FOR Sponsor Responsibility and Delegation of Responsibility Approval: Nancy Paris, MS, FACHE President and CEO (17 July 2014) (Signature and
More informationWIRBinar. How to Survive an FDA Inspection. Upcoming Trainings: Contact Us: (360)
WIRBinar How to Survive an FDA Inspection 10-26-2011 Brought to you by WIRB Education and Consulting Services. Improve your ability to maintain compliance and protect human subjects with guidance from
More informationNEWCASTLE CLINICAL TRIALS UNIT STANDARD OPERATING PROCEDURES
NEWCASTLE CLINICAL TRIALS UNIT STANDARD OPERATING PROCEDURES SOP details SOP title: Site Selection and Initiation SOP number: TM-005 SOP category: Trial Management Version number: 04 Version date: 10 July
More informationSuccessful FDA Inspections at Investigative Sites for Clinical Trials of Drugs and Biologics
Vol. 9, No. 1, January 2013 Happy Trials to You Successful FDA Inspections at Investigative Sites for Clinical Trials of Drugs and Biologics By Swati Tendolkar The United States Food and Drug Administration
More informationSTANDARD OPERATING PROCEDURE
STANDARD OPERATING PROCEDURE Title Reference Number Corrective and Preventative Action SOP-QMS-008 Version Number 2 Issue Date 29 th Sep 2016 Effective Date 10 th Nov 2016 Review Date 10 th Nov 2018 Author(s)
More informationmanaging or activities.
STANDARD OPERATING PROCEDURE Clinical Research Monitoring TITLE: Site Initiation Visit TITLE: Site Initiation Visit 1. PURPOSE SOP Number: Version: 1.0 MICHR CRM MON 002 Effective Date: 19Dec2013 1.1 This
More informationFDA Inspection Readiness
FDA Inspection Readiness Richard Angelo, Ph.D. Director, Managing Consultant October 17, 2014 Agenda Reasons for Inspections Preparing for Inspections Inspection Day Inspection Outcomes 2013 Inspection
More informationSTUDY INFORMATION POST-IRB APPROVAL FDA DEVICE (IDE) SPONSOR AND INVESTIGATOR RESPONSIBILITY (21 CFR 812)
POST-IRB APPROVAL FDA DEVICE (IDE) SPONSOR AND INVESTIGATOR RESPONSIBILITY (21 CFR 812) Purpose: Investigators who initiate and submit an IDE application to the FDA assume the responsibilities of both
More informationBiomedical IRB MS #
Department for Human Research Protections Institutional Review Boards Biomedical IRB MS # 1035 419-383-6796 IRB.Biomed@utoledo.edu Social, Behavioral and Educational IRB MS # 944 419-530-6167 IRB.SBE@utoledo.edu
More informationQUALITY TIPS FOR CLINICAL SITES. Athena Thomas-Visel. Clinical Quality Consultant QUALITY TIPS FOR CLINICAL SITES
QUALITY TIPS FOR CLINICAL SITES Athena Thomas-Visel Clinical Quality Consultant QUALITY TIPS FOR CLINICAL SITES Purpose of presentation: Share best practices seen from 150+ sites visited Spark conversation
More informationQUALITY ASSURANCE PROGRAM
QUALITY ASSURANCE PROGRAM Elaine Armstrong, MS Quality Assurance Manager PURPOSE Verify accuracy of submitted data Verify compliance with protocol and regulatory requirements Provide educational support
More informationSTANDARD OPERATING PROCEDURE SOP 710. Good Clinical Practice AUDIT AND INSPECTION. NNUH UEA Joint Research Office. Acting Research Services Manager
STANDARD OPERATING PROCEDURE SOP 710 Good Clinical Practice AUDIT AND INSPECTION Version 1.3 Version date 27.02.2018 Effective date 3.03.2018 Number of pages 10 Review date February 2020 Author Role Approved
More informationEMA Inspection Site perspective
EMA Inspection Site perspective Hermien Gous Wits RHI Shandukani Research Centre 27.09.2016 Cape Town Why were we inspected times? Pharmaceutical company applied for registration of the study drug in a
More informationUNC Lineberger Comprehensive Cancer Center. Data and Safety Monitoring Plan
UNC Lineberger Comprehensive Cancer Center Data and Safety Monitoring Plan Norman E. Sharpless, MD, Director P30CA-16086 Approved: September 29, 2014 Table of Contents Monitoring Progress of Trials and
More informationWhen a Single IRB Reviews for Multiple Sites:
When a Single IRB Reviews for Multiple Sites: The Complexities of Simplification John Ennever, MD, PhD Director Office of Human Research Affairs Boston Medical Center and Boston University Medical Campus
More informationDO I NEED TO SUBMIT FOR THIS?... & OTHER FREQUENTLY ASKED QUESTIONS. March 2015 IRB Forum
DO I NEED TO SUBMIT FOR THIS?... & OTHER FREQUENTLY ASKED QUESTIONS March 2015 IRB Forum Topics Quality Assurance/Quality Improvement Projects Informed Consent- when is a waiver appropriate? Retrospective/Prospective
More informationInspections and Study Monitoring
Inspections and Study Monitoring IRB Education Series 2006 Presentation may only be reused or reprinted with written permission from the Tufts-New England Medical Center/Tufts University IRB office. Audits
More informationNEWCASTLE CLINICAL TRIALS UNIT STANDARD OPERATING PROCEDURES
NEWCASTLE CLINICAL TRIALS UNIT STANDARD OPERATING PROCEDURES SOP details SOP title: Site Selection and Initiation SOP number: TM 005 SOP category: Trial Management Version number: 03 Version date: 19 December
More informationUniversity of Illinois at Chicago Human Subjects Protection Program Plan
Office for the Protection of Research Subjects (OPRS) Institutional Review Board FWA# 00000083 University of Illinois at Chicago Human Subjects Protection Program Plan 203 AOB (MC 672) 1737 West Polk Street
More informationSAINT AGNES MEDICAL CENTER CLINICAL RESEARCH CENTER Fresno, California. STANDARD OPERATING PROCEDURES Institutional Review Board
SAINT AGNES MEDICAL CENTER CLINICAL RESEARCH CENTER Fresno, California STANDARD OPERATING PROCEDURES Institutional Review Board Date Effective: April 26, 2001 Index No. R 1217 Date Last Revised: 0 Date
More informationMastering Clinical Research April 19, :30 am
Mastering Clinical Research April 19, 2017 7:30 am New Question and Answer Response System Log In Directions Use the following link to access pre and post test questions: http://www.socrative.com/ Click
More informationStandard Operating Procedure INVESTIGATOR OVERSIGHT OF RESEARCH. Chief and Principal Investigators of research sponsored and/or hosted by UHBristol
Standard Operating Procedure INVESTIGATOR OVERSIGHT OF RESEARCH SETTING FOR STAFF ISSUE Trustwide Chief and Principal Investigators of research sponsored and/or hosted by UHBristol Oversight of research
More informationPROTOCOL-SPECIFIC DOCUMENT
PROTOCOL-SPECIFIC DOCUMENT To Collect Institutional Requirements from Relying Institutions Institutional, Local, and State Requirements Working Group of the SMART IRB Harmonization Steering Committee February
More informationChanges to the Common Rule
Changes to the Common Rule November 21, 2017 S Joseph Austin, JD, LL.M Corey Zolondek, PhD, CIP Introduction: NOTE: Relative to the Common Rule changes, this presentation does not address requirements
More informationGeneral Administration GA STANDARD OPERATING PROCEDURE FOR Document Development and Change Control
General Administration GA 104.00 STANDARD OPERATING PROCEDURE FOR Document Development and Change Control Approval: Nancy Paris, MS, FACHE President and CEO 08 March 2012 (Signature and Date) Approval:
More informationNCI and VA Interagency Group to Accelerate Trials Enrollment (NAVIGATE) Request for Applications (RFA)
NCI and VA Interagency Group to Accelerate Trials Enrollment (NAVIGATE) Request for Applications (RFA) Release Date: November 15, 2017 SUBMISSION: DUE ON: SUBMIT TO: LETTER OF INTENT (as PDF file) 5 pm
More informationRegulatory Inspections
Regulatory Inspections An Overview of Process, Observations, and Guidance for Investigators Alison Urton, Group Administrator Clive Hansen, Audit Team Leader Outline Regulatory History Health Canada Overview
More informationHow to Prepare for Federal Inspections and What to Expect
How to Prepare for Federal Inspections and What to Expect Jennifer A. Graf Tufts Medical Center Tufts University Health Sciences Director of IRB Operations Originally presented at the February 2011 Society
More informationCOMPLIANCE WITH THIS PUBLICATION IS MANDATORY
BY ORDER OF THE SECRETARY OF THE AIR FORCE AIR FORCE INSTRUCTION 65-402 19 JULY 1994 Financial Management RELATIONS WITH THE DEPARTMENT OF DEFENSE, OFFICE OF THE ASSISTANT INSPECTOR GENERALS FOR AUDITING,
More informationUNIVERSITY OF SOUTHERN MAINE Office of Research Integrity & Outreach
UNIVERSITY OF SOUTHERN MAINE Office of Research Integrity & Outreach Procedure #: IACUC - 001 Date Adopted: May 5, 2017 Last Updated: Prepared By: Casey Webster, Research Compliance Administrator Reviewed
More informationStandard Operating Procedures
Standard Operating Procedures 5.7 Site Initiation Version V1.0 Author/s Approved B Fazekas, S Kochovska D Currow Effective date 30/09/2017 Review date 30/09/2019 DO NOT USE THIS SOP IN PRINTED FORM WITHOUT
More informationOffice of the Vice Chancellor for Research Supervisory Responsibilities of Clinical Investigators
Office of the Vice Chancellor for Research Supervisory Responsibilities of Clinical Investigators Patricia Fischer, RN, CCRP Investigator Responsibilities FDA Draft Guidance May 2007 Clarifies FDA s expectations,
More informationMARKEY CANCER CENTER CLINICAL RESEARCH ORGANIZATION STANDARD OPERATING PROCEDURES SOP No.: MCCCRO-D
Page 1 of 8 MARKEY CANCER CENTER CLINICAL RESEARCH ORGANIZATION STANDARD OPERATING PROCEDURES SOP No.: Title: Data Safety and Monitoring Committee Administrative and Revision: N/A Revision Date: N/A Functional
More informationUniversity of South Carolina. Unanticipated Problems and Adverse Events Guidelines
University of South Carolina Unanticipated Problems and Adverse Events Guidelines These guidelines define the procedures of USC for addressing unanticipated problems involving risks to research participants
More informationDr. R. Sathianathan. Role & Responsibilities of Principal Investigators in Clinical Trials. 18 August 2015
18 August 2015 Role & Responsibilities of Principal Dr. R. Sathianathan Professor of Psychiatry, SRMC, Porur & Former Director, Institute of Mental Health, Chennai Principal Investigators & GOOD CLINICAL
More informationUNIVERSITY MEDICAL CENTER NEW ORLEANS RESEARCH REVIEW APPLICATION
UNIVERSITY MEDICAL CENTER NEW ORLEANS RESEARCH REVIEW APPLICATION Submission and Approval Process 1. Submit complete RRC application to Office of Research as early as possible in study process. 2. Quality
More informationAccelerated Translational Incubator Pilot (ATIP) Program. Frequently Asked Questions. ICTR Research Navigators January 19, 2017 Version 7.
Accelerated Translational Incubator Pilot (ATIP) Program Frequently Asked Questions ICTR Research Navigators January 19, 2017 Version 7.0 TABLE OF CONTENTS Section # Title Page 1. ABOUT THE ATIP PROGRAM...
More informationPrivacy Board Standard Operating Procedures
Privacy Board Standard Operating Procedures Page 1 of 12 I. Background The Health Insurance Portability and Accountability Act ( HIPAA ) generally requires specific compliance reviews and documentation
More informationUSING SMART IRB AND SINGLE IRB REVIEW
USING SMART IRB AND SINGLE IRB REVIEW Jeannie Barone Director, HRPO ATTRIBUTES Special thanks to Nichelle Cobb, PhD from University of Wisconsin-Madison for her permission to utilize her slides on SMART
More informationLOUIS STOKES CLEVELAND VA MEDICAL CENTER RESEARCH SERVICE Human Subject Protection Standard Operating Procedure (SOP)
LOUIS STOKES CLEVELAND VA MEDICAL CENTER RESEARCH SERVICE Human Subject Protection Standard Operating Procedure (SOP) Effective Date: February 7, 2013 SOP Title: Study Monitoring Visits - Process for Access
More informationTop Ten Issues to Avoid in Grant Congruency
Top Ten Issues to Avoid in Grant Congruency Michelle Watkinson, CIP Senior IRB Administrator, Arts & Sciences IRB and Farah Anwar IRB Administrator, Arts & Sciences IRB Objectives Learn the difference
More informationPrepared by the American College of Radiology Imaging Network Protocol Development and Regulatory Compliance Department
AUDIT MANUAL Prepared by the American College of Radiology Imaging Network Protocol Development and Regulatory Compliance Department Original: October 2001 Revised: June 2010 American College of Radiology
More informationThe Greenville Hospital System Office of Research Compliance and Administration HRPP Policies and Procedures
The Greenville Hospital System Office of Research Compliance and Administration HRPP Policies and Procedures Title: Western Institutional Review Board (WIRB) HRPP Policy No. 33.02 Effective Date: May 2012
More informationThe GCP Perspective on Study Monitoring
The GCP Perspective on Study Monitoring Heidi Judge, CCRP Sr. Clinical Trials Project Manager Clinical Trials Network and Institute Massachusetts General Hospital 1 Overview Monitoring Basics Who, What,
More informationQuality Assurance and Regulatory Compliance Office and USAMRIID FDA Risk Management. Carolyn Mentzer Chief, QARCO
Quality Assurance and Regulatory Compliance Office and USAMRIID FDA Risk Management Carolyn Mentzer Chief, QARCO 301-619-3422 Who We Are and What We Do USAMRIID s mission is to conduct basic and applied
More informationUNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER INSTITUTIONAL REVIEW BOARD REPORTING UNANTICIPATED PROBLEMS INCLUDING ADVERSE EVENTS
UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER INSTITUTIONAL REVIEW BOARD REPORTING UNANTICIPATED PROBLEMS INCLUDING ADVERSE EVENTS I. PURPOSE To specify the procedures for reporting unanticipated problems,
More informationSOP : Quality Assurance Inspections SCOPE RESPONSIBILITIES. APPROVAL AUTHORITY EFFECTIVE DATE May PURPOSE 2.
TITLE SCOPE RESPONSIBILITIES APPROVAL AUTHORITY EFFECTIVE DATE May 2018 901: Quality Assurance Inspections All research submitted to the University of British Columbia s Research Ethics Boards The Vice
More informationStudy Start-Up SS STANDARD OPERATING PROCEDURE FOR PRE-STUDY SITE VISIT (PSSV)
Replaces previous version 203.01: 01 July 2014 Study Start-Up SS 203.01 STANDARD OPERATING PROCEDURE FOR PRE-STUDY SITE VISIT (PSSV) Approval: Nancy Paris, MS, FACHE President and CEO 24 May 2017 (Signature
More informationSystem to Track and Approve Research STAR Principal Investigator/Proxy User Guide
System to Track and Approve Research STAR Principal Investigator/Proxy User Guide Research Administration 125 Worth Street, 4 th Floor New York, NY 10013 Contents I) BACKGROUND INFORMATION... 3 II) ACCESSING
More informationEffective Date: November 12, 2015 Policy Number: MHC_RP0306. Corporate Director, HRPP Institutional Official, HRPP
Policy Title: Education and Training In Human Subject Research Effective Date: November 12, 2015 Policy Number: Review Date: November 12, 2015 Section: Revised Date: Administrative Responsibility: Oversight
More informationTANZANIA CIVIL AVIATION AUTHORITY AERODROMES AND AIR NAVIGATION SERVICES. Foreword
AERODROMES AND AIR NAVIGATION SERVICES Revision: 1 Title: ANS Inspector Handbook Page 1 of 62 Foreword The Civil Aviation safety oversight program has been implemented to promote and ensure conformance
More informationTrial set-up, conduct and Trial Master File for HEY-sponsored CTIMPs
R&D Department Trial set-up, conduct and Trial Master File for HEY-sponsored CTIMPs Hull And East Yorkshire Hospitals NHS Trust 2010 All Rights Reserved No part of this document may be reproduced, stored
More informationDocument Title: Study Data SOP (CRFs and Source Data)
Document Title: Study Data SOP (CRFs and Source Data) Document Number: SOP047 Staff involved in development: Job titles only Document author/owner: Directorate: Department: For use by: RM&G Manager, R&D
More informationDocument Number: 006. Version: 1. Date ratified: Name of originator/author: Heidi Saunders, Senior Portfolio Coordinator
including Roles and Responsibilities for the Conduct of Research Studies and Clinical Trials including CTIMPs (Clinical Trials of Investigational Medicinal Products) Document Number: 006 Version: 1 Ratified
More informationResearch Compliance Oversight in the Department of Veterans Affairs
Research Compliance Oversight in the Department of Veterans Affairs Karen M. Smith, PhD Director, Midwestern Regional Office Office of Research Oversight Department of Veterans Affairs Health Care Compliance
More informationMargaret Huber, RN, CHRC Compliance Consultant Office of Research Compliance
Margaret Huber, RN, CHRC Compliance Consultant Office of Research Compliance 4/20/2015 Objectives Define monitoring and explain why monitoring is important in clinical trials Provide an overview of the
More informationThe Mammography Quality Standards Act Final Regulations Quality Assurance Documentation
Compliance Guidance The Mammography Quality Standards Act Final Regulations Quality Assurance Documentation Document issued on December 7, 1999 U.S. Department Of Health And Human Services Food and Drug
More informationAuditing of Clinical Trials
Version 1.2 Effective date: 3 September 2012 Author: Approved by: Claire Daffern, QA Manager Dr Sarah Duggan, CTU Manager Revision Chronology: Effective Date Version 1.2 3 Sept 2012 Version 1.1 12 May
More information*Applicable to: Beaumont Health. Document Type: Policy
Owner: *For This Document, Includes: Beaumont Corporate Shared Services Beaumont Hospital, Dearborn Beaumont Hospital, Farmington Hills Beaumont Hospital, Grosse Pointe Beaumont Hospital, Royal Oak Beaumont
More informationToward Greater Scientific Rigor
Toward Greater Scientific Rigor Good Clinical Practice (GCP) A NEW REQUIREMENT! The Center for Clinical & Translational Science 205.934.7442 ccts@uab.edu www.uab.edu/ccts @cctsnetwork The requirement:
More informationResearch Policy. Date of first issue: Version: 1.0 Date of version issue: 5 th January 2012
Research Policy Author: Caroline Mozley Owner: Sue Holden Publisher: Caroline Mozley Date of first issue: Version: 1.0 Date of version issue: 5 th January 2012 Approved by: Executive Board Date approved:
More informationInvestigator Site File Standard Operating Procedure (SOP)
Investigator Site File Standard Operating Procedure (SOP) DOCUMENT CONTROL: Version: 1 Ratified by: Quality and Safety Sub Committee Date ratified: 30 January 2017 Name of originator/author: Research Nurse
More informationInvestigator Roles and Responsibilities in Clinical Device Trials
Investigator Roles and Responsibilities in Clinical Device Trials A Total Product Lifecycle Approach to Medical Device Development: Responsibilities and Opportunities The Stanford Center for Clinical and
More informationSECTION 2: REGISTER YOUR ICU
SECTION 2: REGISTER YOUR ICU Contents Site Registration and Activation... 2 Before you register... 2 Is your Site Suitable?... 2 Obtaining Ethics Clearance... 4 Time to Register!... 6 Registration Tips...
More informationThe Clinical Research Center Research Practice Manual. Guideline for Study Document and Data Handling RPG-08. Guideline. Purpose.
The Clinical Research Center Research Practice Manual Guideline for Study Document and Data Handling RPG-08 Purpose Guideline This Guideline provides functional definitions for common data management terms;
More informationCommonwealth Health Research Board [CHRB] Grant Guidelines and Application Instructions for FY 2019/2020
[CHRB] Grant Guidelines and Application Instructions for FY 2019/2020 Effective July 1, 2018 for Grants to be awarded July 1, 2019 KEY DATES DUE DATES Concept Paper Submissions September 13, 2018 Full
More informationNational Cancer Institute. Central Institutional Review Board. Standard Operating Procedures
National Cancer Institute Central Institutional Review Board Standard Operating Procedures CIRB Standard Operating Procedures Additional copies are available from the CIRB website (http://www.ncicirb.org)
More informationRecord or Document Type Retention Period Relevant Legal Citation(s) IRB Records: Training Records;
TEXAS HEALTH RESOUCES Table 17-III. Record Retention Schedule Human Subject Research Records and Documents Approved by THR System Performance Council (SPC): 19 January 2010 Effective Date: October 14,
More informationTitle: Investigator Responsibilities. SOP Number: 1501 Effective Date: June 2, 2017
Previous Version Dates: Title: Investigator Responsibilities SOP Number: 1501 Effective Date: June 2, 2017 1 Purpose Investigators are ultimately responsible for the conduct of research. Investigators
More informationRegulatory Binder Checklist for FDA-Regulated Sponsor/Sponsor-Investigator Studies
Regulatory Binder Checklist for FDA-Regulated Sponsor/Sponsor-Investigator Studies DIRECTIONS: 1. The purpose of a regulatory binder is to assure that all essential elements are maintained in an organized
More informationEffective Date: 11/09 Policy Chronicle:
Title: Investigational Drug Service Functions Policy Type: Clinical Operations Replaces (supersedes): Title: N/A Policy Chronicle: Date Original Version of Policy was Effective: 09/06 Reviewer Signature:
More informationTitle: Corporate Compliance - Clinical Trials or Research Involving an Investigational Device Exemption (IDE) - Policy
Involving an Investigational Device Exemption (IDE) - Policy Document Owner: Jennifer May Content Expert: Lori Wilcox Last Approved Date: 08/09/2016 Printed copies are for reference only. Please refer
More informationSARASOTA MEMORIAL HOSPITAL CANCER RESEARCH PROGRAM POLICY
PS1006 SARASOTA MEMORIAL HOSPITAL CANCER RESEARCH PROGRAM POLICY TITLE: Satellite Site Management Plan Job Title of Reviewer: POLICY #: EFFECTIVE DATE: REVISED DATE: POLICY TYPE: Elizabeth Carr, R.N.,
More informationARIZONA STATE UNIVERSITY PROCEDURES FOR THE REVIEW OF HUMAN SUBJECTS RESEARCH LAST REVISION DATE 5/3/17
ARIZONA STATE UNIVERSITY PROCEDURES FOR THE REVIEW OF HUMAN SUBJECTS RESEARCH LAST REVISION DATE 5/3/17 Susan Metosky IRB Administrator Office of Research Integrity and Assurance Susan.Metosky@asu.edu
More informationPre-Submissions and Meetings with FDA Staff
Pre-Submissions and Meetings with FDA Staff Soma Kalb, PhD Acting Director, IDE Program Office of Device Evaluation Elizabeth Hillebrenner, MSE Policy Analyst Office of In Vitro Diagnostics & Radiological
More informationClinical Research Seminar
Clinical Research Seminar HOW TO DEVELOP A CORRECTIVE AND PREVENTIVE ACTION PLAN (THAT EVEN THE IRB AND FDA WILL LOVE) April 11, 2018 Fiona Rice, MPH Human Research Quality Manager fionar@bu.edu Mary-Tara
More informationDocument Title: Recruiting Process. Document Number: 011
Document Title: Recruiting Process Document Number: 011 Version: 1.0 Ratified by: Committee Date ratified: 24.06.2014 Name of originator/author: Directorate: Department: Name of responsible individual:
More informationIN ACCORDANCE WITH THIS INTERNATIONAL DEVICE STANDARD
COMPLIANCE WITH ISO 14155:2011 GUIDANCE FOR ENSURING YOUR CLINICAL STUDY IS BEING DESIGNED, EXECUTED, AND MONITORED IN ACCORDANCE WITH THIS INTERNATIONAL DEVICE STANDARD Introduction: An increasing trend
More informationUConn Health Office of Clinical & Translational Research Standard Operating Procedures
Purpose and Applicability: To ensure that a Medicare Coverage Analysis is done by staff in OCTR for all research clinical trials that produce r routine clinical services (RC) to be billed to Medicare and
More informationInstitutional Review Board Standard Operating Procedures. Education and Training on Human Subject Research Date Last Revised: OVERVIEW
Page 1 of 6 Document Number: IRB-P106 Version Number: 1.3 Institutional Official: David Carlisle, MD, PhD Title: Institutional Review Board Standard Operating Procedures Education and Training on Human
More informationACTIONS/PSOP/001 Version 1.0 Page 2 of 6
1. The purpose of the Pharmacy Site File To enable the designated trust pharmacy to fulfil its role and exercise appropriate control over all aspects of study medication handling, an accurately maintained
More informationEffectively Managing and Monitoring Controlled Substances in Research
Effectively Managing and Monitoring Controlled Substances in Research Emmelyn Kim, MA, MPH, CCRA, CHRC AVP, Research Compliance & Privacy Officer Ji Eun Kim, PhD, RPh Research Pharmacist The Office of
More informationTopics 5/16/2017. Effectively Managing and Monitoring Controlled Substances in Research
Effectively Managing and Monitoring Controlled Substances in Research Emmelyn Kim, MA, MPH, CCRA, CHRC AVP, Research Compliance & Privacy Officer Ji Eun Kim, PhD, RPh Research Pharmacist The Office of
More informationUtilizing the NCI CIRB
Policy P15 Written By: B. Laurel Elder, Ph.D. Created: September 2, 2011 Edited Version P15.1 Utilizing the NCI CIRB PURPOSE - The purpose of this Standard Operating Procedure (SOP) is to outline the procedures
More information